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SUATU PENILAIAN KEADAAN  DAN PENGETAHUAN OSTEOPOROSIS 
DALAM KALANGAN PENGGUNA WARFARIN DI HOSPITAL DI 
WILAYAH UTARA, SEMENANJUNG  MALAYSIA 
 
1 ABSTRAK 
             Osteoporosis ialah penyakit kronik yang mempunyai hubungan kompleks 
dengan pesakit yang menggunakan warfarin. Dalam usaha menyediakan pengurusan 
osteoporosis yang optima, nasihat untuk pesakit yang menggunakan warfarin adalah 
amat diperlukan. Sebahagian dari data klinikal yang terlibat dalam kajian kawalan 
kes dengan menggunakan kaedah persampelan mudah dengan 270 subjek (kumpulan 
kawalan dan pesakit) telah diambil untuk menilai status kesihatan tulang dengan 
mengukur ketumpatan mineral tulang (BMD)  menggunakan imbasan ultrasound 
kuantitatif (QUS) untuk menilai juga pengetahuan osteoporosis (OKT). Keputusan 
QUS menunjukkan bahawa kelaziman BMD yang normal, osteopenia, dan 
osteoporosis ialah 23.3%, 53.7% dan 23%. Masing-masing kajian ini menunjukkan 
bahawa lebih tiga perempat kumpulan pesakit (82%) mempunyai risiko tinggi dalam 
ketumpatan mineral tulang (BMD) yang tidak normal. Pengguna warfarin 
menunjukkan kebarangkalian dua kali ganda lebih tinggi untuk mengalami 
osteoporosis berbanding dengan kumpulan kawalan. Tambahan pula, BMD 
mempunyai hubungan negatif dengan umur, tetapi mempunya hubungan positif 
dengan indeks jisim badan (BMI). Pesakit menunjukkan hubungan negatif dengan 
pengambilan warfarin pada dos yang tinggi. Selain itu, nisbah ganjil dalam kalangan 
wanita yang menggunakan warfarin mendapat skor insiden osteoporosis yang lebih 
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tinggi iaitu 2.4 kali ganda berbanding wanita yang tidak menggunakan warfarin. 
Berhubung perkara ini, wanita berbangsa Cina (berumur lebih daripada 50 tahun), di 
bawah terapi warfarin selama lebih daripada setahun, adalah lebih terkesan dalam 
pengurangan BMD jika dibandingkan dengan wanita Melayu atau India. 
Konklusinya, pesakit yang menggunakan warfarin mempunyai risiko yang lebih 
tinggi untuk menghidap osteoporosis berbanding dengan kumpulan kawalan. 
Bangsa, sejarah keluarga dalam tulang patah dan umur boleh dianggap sebagai faktor 
risiko osteoporosis yang signifikan ketika terapi warfarin yang kronik. Keputusan 
menunjukkan kumpulan kawalan, 69.3% daripada mereka mempunyai risiko tinggi 
untuk BMD yang tidak normal berdasarkan klasifikasi yang ditetapkan WHO. 
Ukuran QUS menujunkkan bahawa 35% daripada bangsa Cina, 33% daripada 
bangsa India dan 32% daripada bangsa Melayu mempunyai risiko yang tinggi untuk 
mengalami osteoporosis. Kajian juga menunjukkan pengurangan parameter QUS (T-
score, BUA, SOS dan SI) dengan mengambil kira umur. Nilai purata untuk lelaki 
(pengguna dan bukan pengguna) adalah lebih tinggi.Untuk tahap pengetahuan 
osteoporosis, kajian menunjukkan subjek (kawalan dan pesakit) mempunyai tahap 
pengetahuan osteoporosis yang rendah. Terdapat perkaitan yang siginifikan antara 
kumpulan (pengguna dan bukan pengguna warfarin) dan tahap pengetahuan 
mengenai osteoporosis (tinggi atau rendah). Kajian menyatakan majority daripada 
responden (82.4%) mempunyai pengetahuan yang rendah bmengenai osteoporosis 
(hanya 15.8% sampel kajian didapati mempunyai OKT yang tinggi). Terdapat 
perbezaan yang ketara dalam kedudukan min antara pembolehubah yang 
mempengaruhi skor OKT. Untuk bangsa pula, bangsa Cina mencatatkan kedudukan 
min OKT yang lebih tinggi berbanding orang Melayu dan India. Untuk pendapatan 
xiv 
 
bulanan, peserta kajian yang memperoleh pendapatan lebih daripada RM2000 
mencatatkan kedudukan yang tinggi untuk pengetahuan osteoporosis. Selain itu, 
berdasarkan pekerjaan pula, peserta kajian yang bekerja mempunyai tahap 
pengetahuan yang lebih tinggi. Peserta yang tinggal di bandar mempunyai 
pengetahuan yang lebih, di mana pesakit mempunyai pengetahuan lebih daripada 
kumpulan kawalan (nisbah ganjil [OR]=4.1, 95% CI: 1.90- 8.69). Dapatan kajian ini 
menunjukkan bahawa kebanyakan orang mempunyai pengetahuan yang sedikit 
mengenai osteoporosis. Pegawai kesihatan sepatutnya memainkan peranan yang 
penting dalam menjelaskan faktor-faktor risiko osteoporosis terhadap pesakit dan 
komuniti.  
. 
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AN ASSESSMENT OF OSTEOPOROSIS CONDITION AND KNOWLEDGE 
AMONG WARFARIN USERS AT A HOSPITAL IN THE NORTHERN 
REGION OF PENINSULAR MALAYSIA 
 
2 ABSTRACT 
         Osteoporosis is a chronic disease that has a complex relation with patients 
using warfarin. In order to provide optimal management of osteoporosis, there is a 
need to advice patients about the usage of warfarin.  A clinical part involved case-
control study of a convenient sample of 270 subjects (controls and patients)  
recruited to assess the bone health status by measuring the bone mineral density 
(BMD) using quantitative ultrasound scan (QUS) as well as to evaluate their 
osteoporosis knowledge (OKT). The result of QUS showed that the prevalence of 
normal BMD, osteopenia, and osteoporosis were 23.3%, 53.7%, 23% respectively. 
This study showed that more than three-quarter patients group (82%) were at high 
risk of abnormal body mass density (BMD). The warfarin users were two times more 
likely to have a higher osteoporosis risk compared to control group. Moreover, BMD 
has a negative correlation with age, but has a positive correlation with body mass 
index (BMI). Patients showed a negative correlation with a higher dose of warfarin 
intake. In addition, odd ratio of females using warfarin scored higher incidence of 
osteoporosis by 2.4 times more than females who did not use warfarin.  In this 
regard, Chinese females (more than 50 years old), under warfarin therapy for more 
than one year, were more affected for the reduction in BMD as compared  to Malay 
or Indian females. In conclusion, patients who used warfarin are at a higher risk of 
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osteoporosis than the controls. Race,family history fracture, and age  were 
considered as significant risk factors of osteoporosis during chronic therapy of 
warfarin.  The result showed the control subjects, 69.3% of subjects had a high risk 
of abnormal BMD based on WHO classification .  The QUS measurement showed 
that 35% of Chinese, 33% of Indians, and 32% of Malays   had high- risk OP. A 
study illistered decrease in all QUS parameters (T- score, BUA, SOS, and SI) with 
regard to age. The average value for men (users and non-users) was higher than the 
one for.  As for the knowledge of osteoporosis, the study revealed that  the subjects 
(controls and patients) had a low level of osteoporosis knowledge. A significant 
association was found between groups (users and non- users warfarin) and level of 
osteoporosis knowledge (high or low). This study indicated that the majority of the 
respondents (84.2%) have a low knowledge score of osteoporosis (Only 15.8% of 
study sample was found to have high OKT). There was a significant difference in 
mean ranks between variables affecting OKT score. With regard to race, Chinese 
recorded higher mean rank of OKT than Malays and Indians. As for   monthly 
income, participants who earned more than RM 2000 recorded higher rank for 
knowledge . With regard to occupation, participants who work for any reasons got 
higher rank knowledge. Urban participants had more knowledge, Patients had more 
knowledge than controls (odds ratio [OR] =4.1, 95% CI: 1.90- 8.69).  The findings 
of this study revealed that most people have inadequate knowledge about 
osteoporosis. The heath care professional should play an active role in educating 
their patients and community about the risk factors of osteoporosis.  
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1 CHAPTER 1                                                                                                 
INTRODUCTION 
1.1 Overview 
Osteoporosis is a silent disease that constitutes a great socio-economic 
problem, with a negative impact on both  morbidity and mortality (Hadjidakis et al., 
2005; Reyes & Moreno, 2005). It is not symptomatic (painless weakening of the 
bones) and may not be detected until a fracture occurs due to  increased skeletal 
fragility and micro architectural deterioration of the bone tissue, thus  a decrease in 
Bone Mineral Density (BMD), bone quality and strength (Cooper & Melton, 1992; 
Nicodemus & Folsom, 2001). The true occurrence of osteoporosis may be 
significantly underestimated because many women who suffer minimal trauma 
fractures are still  not being evaluated for osteoporosis (Siris et al., 2006). 
Osteoporosis can result in height loss, severe back pain, deformity, or impairment of 
a person’s ability to walk, disability, and even death (Heinemann & Donna, 2000; 
Salkeld et al., 2000). Caucasian and Asian women are at the highest risk of 
developing osteoporosis. However, Black and Hispanic women are also at significant 
risk. The point of identifying and evaluating populations at increased risk of 
developing osteoporosis is critical to disease prevention and management (Aloia et 
al., 1996; Luckey et al., 1996; National Institutes of Health  (NIH), 2001). 
The burden of osteoporosis is expressed not only in the economic costs 
companying (Lindsay, 1995; Ray et al., 1997), but also in its psychological and 
social consequences. The physical complications of the disease may be serious and 
includes pain, functional limitation and increased morbidity and mortality (Wolf et 
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al., 2000). Social and psychological effects include loss of independence, inability to 
work, isolation, decreased quality of life and diminished self-esteem and depression 
(Gold et al., 1998; Lips et al., 1999). 
The prevalence of osteoporosis in Malaysia was reported as 24.1% in 2005, 
predominantly affecting the hip (Loh & Shong, 2007). Meanwhile, the rates of hip 
fracture are twofold higher in Hong Kong (Gullberg et al., 1997). In contrast, the 
prevalence of osteoporosis was  found much lower in Thailand (12.6%),  China 
(16.1%) and  Taiwan (10.08%) (Lau et al., 2001). The overall prevalence of 
osteoporosis in the Asian population is higher than the western countries due to the 
fact that the Asian population has lower body mass index and shorter height (Loh & 
Shong, 2007). 
The World Health Organization (WHO) has formed a working group in 1994 
to define osteoporosis. Osteoporosis is defined as "a progressive systemic skeletal 
disease characterized by low bone mass and micro architectural deterioration of bone 
tissue, below the young adult mean with the presence of one or more fragility 
fracture (Kanis et al., 1994). 
 Osteoporosis is a clinical syndrome characterized by the failure of osteoclasts 
to resorb bone. Consequently, bone modelling and remodelling are impaired. The 
defect in bone turnover characteristically results in skeletal fragility despite increased 
bone mass, and it may also cause hematopoietic insufficiency, disturbed tooth 
eruption, nerve entrapment syndromes, and growth impairment. Although human 
osteoporosis is a heterogeneous disorder encompassing different molecular lesions 
and a range of clinical features, all forms share a single pathogenic nexus in the 
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osteoclast (Stark & Savarirayan, 2009). Osteoporosis was first described in 1904, by 
German radiologist, Albers-Schönberg (Cleiren et al., 2001). 
 
1.2 Diagnosis of Osteoporosis   
Most patients are asymptomatic and diagnosis is made only after a fracture. Common 
clinical presentations include: 
1. Increased dorsal kyphosis (Dowager’s hump) 
2. Low-trauma fracture 
3. Loss of height 
4. Back pain 
The diagnosis of primary osteoporosis can be detected after excluding 
secondary causes of bone loss. A clinical evaluation, which includes a careful 
history, physical examination and appropriate laboratory investigations, is 
mandatory. Although multiple risk factor assessment does not predict bone mass 
with sufficient precision (Slemenda et al., 1990), it remains the mainstay in decision 
making to identify the ‘at-risk’ patient requiring further investigation. 
The prevalence of osteoporosis related fractures has increased in many 
countries around the world and this trend is expected to continue as the population 
ages. Although the majority of osteoporotic fractures currently occur in European 
countries, by the year 2050, over half of all hip fractures are predicted to occur in 
Asian countries (Cooper et al., 1992). In addition, osteoporosis is more common in 
Caucasian women but is a growing concern for men and other ethnicities (Tung & 
Lee, 2006). It is estimated that ten million individuals have osteoporosis and another 
thirty-four million suffer from low bone density. By 2020, approximately sixty-one 
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million individuals will have osteoporosis or low bone density (Heinemann & 
Donna, 2000). As bone strength decreases, the risk of fractures increases. The 
increased risk of fractures has led to increased morbidity and mortality of individuals 
living in the US (Woolf & Åkesson, 2003). In Malaysia, hip fractures as a result of 
osteoporosis affected 218 women per 100,000 (Lau et al., 2001), with a direct 
hospitalization cost of RM 22 million (US $6.5 million) (Yeap et al., 2013). Study on 
improving the management of osteoporosis in Malaysia is limited. However, with the 
increasing population of the elderly worldwide as well as in Malaysia, the prevalence 
of osteoporosis is expected to escalate. In 1997, the incidence of hip fracture in 
Malaysia among individuals above 50 years of age was 90 per 100,000. There was a 
marked increase in the incidence among the older age group. The incidence of hip 
fracture is consistently higher in women. In the Malaysian population, hip fractures 
commonly occurred among the Chinese compared to the Malays and Indians with 
44.8% of hip fractures in Chinese women (Lee J.K. & Khir, 2007). Females were 
twice as commonly affected as compared to males. Race and sex-specific incidence 
data showed that the incidence was highest among Chinese females (220 per 100 
000), followed by Indian females (200 per 100 000). 
The age-specific incidence was 500 per 100 000 for patients above 75 years, 
compared to 10 per 100 000 in those between 50 and 54 years (Lee J.K. & Khir, 
2007). The percentage of the Malaysian population aged above 65 years grows 
annually at a rate of 3% and it is projected that by the year 2020, there will be 7.3% 
or 2 million elderly people in the country (Noor & Ismail, 2002). In Malaysia, there 
has been a shift towards a more ‘‘affluent’’ diet and lifestyle, and increased 
prevalence of chronic disease over the past three decades (Tee, 1999). Therefore, 
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osteoporosis may be expected to pose an increasing public health problem if 
appropriate intervention is not taken. Referring to the incidence of nine million 
fractures, 39% occur in men (Johnell & Kanis, 2006). Although men suffer fewer 
fractures than women, they have a significantly higher morbidity and mortality rate 
(Johnell & Kanis, 2006). It is projected that by 2050, 50% of hip fractures will occur 
in Asia, with the majority occurring in China (Cooper et al., 1992). 
 
The WHO diagnostic classification (Table1.1) (World Health Organization 
(WHO) & Food and Agriculture Organization of the United Nations, 1994) is made 
by BMD testing with Dual-energy X-ray Absorptiometry (DXA) using the T-score, 
calculated by subtracting the mean BMD (in g/cm2) of a young adult reference 
population from the patient’s BMD and divided  by the standard deviation (Gold et 
al., 1998; Lips et al., 1999) of the young adult reference population. The 
International Society for Clinical Densitometry recommends that BMD be measured 
at the lumbar spine (L1L4), total hip, and femoral neck, with the 33% radius (1/3 
radius) being measured when the lumbar spine and/or hip cannot be measured (e.g., 
obese patient who exceeds weight) or is invalid (e.g., patient with lumbar 
laminectomy) (Schousboe et al., 2013). Osteoporosis cannot be diagnosed by BMD 
measurement at skeletal sites other than lumbar spine, total hip, femoral neck, and 
33% radius or with technologies other than DXA. The quality of DXA instrument 
maintenance, acquisition, analysis, interpretation, and reporting is important in 
obtaining valid results that can be used for making appropriate clinical decisions. For 
a patient with a fragility fracture, a clinical diagnosis of osteoporosis may be 
considered independently of BMD results, assuming that other causes of skeletal 
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fragility (e.g., osteomalacia) are not responsible for the fracture. Establishing a 
diagnosis of osteoporosis is clinically useful because it facilitates communication 
among healthcare providers and patients concerning a disease with potentially 
serious consequences. In  some countries, such as the United States, a diagnosis is 
necessary in order to select a numerical code for submission of insurance claims for 
reimbursement for medical services (Lewiecki et al., 2006; Schousboe et al., 2013). 
  
The US National Bone Health Alliance (Siris et al., 2014), has recommended 
for osteoporosis to be diagnosed in postmenopausal women and men over the age of 
50 years. (When following circumstances occur, T-score ≤ −2.5 at the lumbar spine 
or hip, low-trauma hip fracture, osteopenia by BMD with a low-trauma vertebral 
proximal Humerus pelvis, or, in some cases, distal forearm fracture, and when a 
Fracture Risk Assessment Tool (FRAX™) shows,  high fracture risk (10-year 
probability of major osteoporotic fracture ≥ 20% or 10-year probability of hip 
fracture ≥ 3%) This sentence needs paraphrasing because it is long and confusing. In 
general, FRAX will not be used if the person is already receiving treatment with 
osteoporosis prescription drugs. The online FRAX tool can be used to estimate the 
10-year probability of fracture risk for overall major osteoporotic fractures (i.e., 
spine, forearm, hip, and shoulder) and hip fracture for women and men aged 40-90. 
In general, a 10-year overall fracture risk of less than 10% is considered low risk; 
10% to 20% is considered moderate risk; and greater than 20% is considered as high 
risk. The only drug-induced osteoporosis drugs evaluated with this tool are 
glucocorticoids, nicotine, and alcohol and may be used with patients taking warfarin. 
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Table 1.1:  World Health Organization criteria for classification of patients with bone 
mineral density measured by dual-energy X-ray absorptiometry 
Classification T-score 
Normal -1.0 or greater 
Low bone mass 
(osteopenia) 
Between - 1.0 and - 2.5 
Osteoporosis -2.5 and below 
Severe osteoporosis -2.5 and below + fragility 
fracture 
 
  However, Hans study, reported that low calcaneus ultrasonographic 
variables were able to predict an increased risk of hip fracture, with similar accuracy 
to low femoral BMD obtained by dual photon x-ray absorptiometry (Hans & Krieg, 
2009). Moreover, QUS has substantial advantages compared with DXA in terms of 
safety, cost, potential portability and its use has been extended to children. The 
calcaneus is the most common skeletal site for QUS assessment because it has a high 
percentage of trabecular bone that is replaced more often than cortical bone, 
providing early evidence of metabolic change. In addition, the calcaneus is fairly flat 
and parallel, reducing repositioning errors. The method can be applied to children, 
neonates, and preterm infants, just as well as to adults. Once micro imaging tools to 
examine specific aspects of bone quality are developed, it is expected that QUS will 
be increasingly used in clinical practice (Guglielmi & Scalzo, 2010). 
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1.3 Fracture Risk Assessment                                                                                
There is an active correlation between BMD and fracture risk with 
approximately a two-fold increase in fracture risk for every 1 SD decrease in BMD 
(Marshall et al., 1996). However, many or most patients with a hip fracture have a T-
score better than -2.5 (Wainwright et al., 2005). Although fracture risk is higher in 
patients with very low BMD, there are numerically many patients with, a T-score 
better than -2.5, with a T-score of -2.5 or worse. Therefore, there are numerically 
more fractures in those with higher T-scores. The presence of Clinical Risk Factors 
(CRFs) that are independent of BMD, particularly age and prior fracture, can help 
identify patients at high risk for fracture by providing information on fracture risk 
that is complementary to BMD. The National Osteoporosis Foundation (NOF) has 
provided an extensive list of CRFs in Table 1.2, for osteoporosis and fractures. Since 
most fractures occur because of a fall (Cosman et al., 2014). 
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Table1.2: Diseases and medications that cause or contribute to osteoporosis and 
fractures  (Cosman et al., 2014). 
 
 
Lifestyle factors 
 
Low calcium intake, Vitamin D insufficiency, Excess of 
vitamin A, High caffeine intake, High salt intake 
Aluminium (in antacids), Alcohol (3 or more drinks/d) 
Inadequate physical activity, Immobilization 
Smoking (active or passive), Falling, Thinness 
 
 
Genetic factors 
Cystic Fibrosis, Homocystinuria, Osteogenesis Imperfecta 
Ehlers-Danlos Syndrome, Hypophosphatasia 
Parental history of hip fracture, Gaucher Disease 
Idiopathic Hypercalciuria, Porphyria, Glycogen Storage D  
Marfan Syndrome, Riley-Day Syndrome, Hemochromatosis 
Menkes Steely Hair Syndrome, Hypogonadal States 
Androgen insensitivity, Hyperprolactinemia 
Turner & Klinefelter Syndromes 
Anorexia Nervosa and Bulimia, Panhypopituitarism 
Athletic Amenorrhea, Premature ovarian failure 
 
Endocrine disorders 
Adrenal insufficiency, Diabetes Mellitus, Thyrotoxicosis 
Cushing Syndrome, Hyperparathyroidism 
Gastrointestinal 
disorders 
Celiac Disease, Inflammatory Bowel Disease. Primary 
Biliary Cirrhosis, Gastric BypassMalabsorption. GI Surgery 
Pancreatic  Disease 
Hematologic 
disorders 
HemophiliaMultiple Myeloma, Systemic Mastocytosis 
Leukemia and Lymphomas, Sickle Cell Disease, Thalassemia 
Rhumatic and 
Autoimmune D 
Ankylosing Spondylitis, Lupus, Rheumatoid Arthritis 
 
Miscellaneous 
conditions 
and Disease 
Alcoholism, Emphysema, Muscular Dystrophy, 
Amyloidosis 
End stage renal disease, Parenteral nutrition 
Chronic metabolic acidosis, Epilepsy 
Post-transplant bone disease, Congestive heart failure 
Idiopathic Scoliosis, Prior fracture as an adult, Depression 
Multiple Sclerosis, Sarcoidosis 
 
Medications 
Anticoagulants (warfarin, heparin), cancer 
chemotherapeutic drugs, gonadotropin releasing hormone 
agonists. Anticonvulsants, cyclosporine A and Tacrolimus, 
lithium. aromatase inhibitors, depo-medroxyprogesterone 
barbiturates 
glucocorticoids (≥ 5 mg/d of prednisone or equivalent for ≥ 3 
mg) 
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1.3.1  Warfarin as risk factor                                                                                   
Coumadin-based oral anticoagulants, referred to as oral anticoagulants, are 
indicated for the prevention and treatment of arterial and venous thromboembolic 
diseases. In the elderly, their main indication is the prevention of ischemic stroke, 
secondary to atrial ﬁbrillation, which has a prevalence of 15% in that population and 
is an independent risk factor for ischemic stroke. The risk of ischemic stroke (5% per 
year) has been reduced with the use of oral anticoagulant which exerts their effect by 
interfering with the action of vitamin K in the process of activation of coagulation 
factors II, VII, IX and X.  These drugs can alter bone metabolism by interfering with 
the activation of osteocalcin, a protein of the bone matrix, which depends on vitamin 
K. Even if the exact role of this protein has not been demonstrated, an increased 
concentration of inactivated osteocalcin associated with vitamin K deﬁciency or 
antagonism caused by the use of oral anticoagulants, has been associated with a 
decrease in hip bone mineral density and a high tended risk of hip fracture (Szulc et 
al., 1994).         
                                               .                                                                         
Warfarin is clinically utilized as an anticoagulant due to its antagonism of 
vitamin K,  essential co-factor role in conferring functionality to blood coagulation 
proteins through the process of gamma carboxylation (Rubinacci, 2009). 
Specifically, the uncarboxylated (non-functional) proteins are converted to their 
carboxylated (functional) forms by vitamin K’s actions. Through the same process, 
vitamin K also confers functionality to skeletal bone Gla proteins, including 
osteocalcin, which plays an important role in bone mineralization (Lam & Cheung, 
2012). Low vitamin K serum concentration and nutritional intake from food 
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frequency questionnaires have been associated with low bone mineral density (Klein 
et al., 2009; You et al., 2005). It has resulted in increased risk of fractures in some 
studies which may be related to the functionality of skeletal bone Gla proteins such 
as osteocalcin (Alan  et al., 2008; You et al., 2005) ). In the carboxylated form, 
osteocalcin binds calcium to the hydroxyapatite (crystal) in bone matrix (Gage. & 
Lesko, 2008; Lindh et al., 2009; Loebstein et al., 2001). ). Indeed, higher levels of 
undercarboxylated osteocalcin and lower levels of carboxylated osteocalcin have 
been associated with fractures, particularly hip fractures, in older adults (Caldwell et 
al., 2008; McDonald et al., 2009). Furthermore, serum concentrations of 
undercarboxylated osteocalcin have been shown to decrease with vitamin K 
supplementation (Sagrieya et al., 2010), and increase with warfarin (Carlquist et al., 
2010).                                                                                            
Thus, as an inhibitor of vitamin-K-dependent gamma carboxylation of Gla 
proteins (Cen et al., 2010), warfarin may lead to bone effects similar to that seen with 
low serum vitamin K levels or high undercarboxylated osteocalcin levels.                          
A common anticoagulant commonly used for preventing and treating 
thromboembolic events in patients with deep vein thrombosis, pulmonary embolism, 
atrial fibrillation and prosthetic heart valves is warfarin. It is a mix of S-warfarin and 
R-warfarin with the former as the more active isomer, thus greater therapeutic effect. 
Various cytochrome P450 enzymes metabolized the enantiomers, specifically the 
cytochrome P450 1A2 (CYP1A2), CYP2C19 and CYP3A4 for the R-warfarin and 
CYP2C9 for the S-warfarin. It affects the activity of vitamin K epoxide reductase 
complex 1 (VKORC1), hence slowing the activation of clotting factors II, VII, IX 
and, X.Warfarin has a narrow therapeutic window and posed deadly consequences if 
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consumed in a wrong dose. Thus, the consumption of warfarin needs to be monitored 
continuously based on the international normalized ratio (Manning et al., 2008), 
Apart from that, the varying response to its dose adds to the difficulty of prescribing 
the right dose for warfarin. Generally, 4–6 weeks of frequent clinic visits, blood tests 
and correct adjustment of dosage are involved in the early stage of warfarin dosing. 
The factors influencing warfarin dosing are patients' clinical characteristics. 
(Loebstein et al., 2001)  and genetic variations. 
 
1.3.2 Vitamin K deficiency as risk factor 
In the past decade, it has become evident that vitamin K has a significant role 
to play in human health that is beyond its well-established function in blood clotting. 
There is a consistent line of evidence in human epidemiologic and intervention 
studies to show that vitamin K can improve bone health. The human intervention 
studies have demonstrated that vitamin K can not only increase bone mineral density 
in osteoporotic people but also actually reduce fracture rates. Furthermore, it is 
evident in human intervention studies that vitamins K and D, a classic in bone 
metabolism, work synergistically on bone density. Most of these studies employed 
vitamin K2 at rather high doses but it has been criticized as a shortcoming of these 
studies. However, there is an emerging evidence in human intervention studies that 
vitamin K1 at a much lower dose may also benefit bone health, in particular when 
co-administered with vitamin D. Several mechanisms are suggested by which 
vitamin K can modulate bone metabolism. Beside the γ-carboxylation of osteocalcin, 
it is assumed that a protein is involved in bone mineralization. There is an increasing 
evidence that vitamin K also positively affects calcium balance, a key mineral in 
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bone metabolism. The Institute of Medicine is part of the United States National 
Library of Medicine, has increased the dietary reference intakes of vitamin K to 90 
μg/d for females and 120 μg/d for males, which is an increase of approximately 50% 
from previous recommendations (Weber, 2001). It is recognized that vitamin K 
insufficiency increases the risk of osteoporosis and hip fractures (Booth et al., 2000). 
As women age, the undercarboxylated osteocalcin increases but not necessarily 
corresponding to decreased vitamin K levels (Plantalech et al., 1991). The non-
carboxylated osteocalcin level was in a range similar to that seen in warfarin-treated 
patients (Plantalech et al., 1991). Those with elevated undercarboxylated osteocalcin 
have decreased bone density and increased risk of hip fracture (Vergnaug et al., 
1997). The optional daily intake of phylloquinone K1 is 1000 μg to maintain 
maximal serum osteocalcin -y- carboxylation (Binkley et al., 2002). 
 
1.3.3 Prevention of osteoporosis                                                      
In the prevention of osteoporosis, sufficient nutrition especially calcium and 
vitamin D intake, is important for bone health. Calcium intake corresponds positively 
to bone mass for individuals of all ages. High and continuous calcium intake since 
young until adolescence produces higher peak bone mass, hence lowering the risk of 
osteoporosis. Other than that, higher calcium intake increased the effectiveness of 
other treatments of osteoporosis such as vitamin D and hormone replacement therapy 
(HRT). Currently, Malaysians consume between 300–400 mg of calcium daily (Chee 
et al., 1997). When the diet is calcium deficient, calcium may be given in the form of 
supplements. The absorption of calcium supplements is highly variable ranging from 
20-40% depending on the formulation. Vitamin D Active individuals who are 
14 
 
exposed to sufficient sunlight (> 15 minutes a day) should have adequate vitamin D 
levels. Elderly who are institutionalised, immobile, lack outdoor activities and have a 
poor diet will benefit from 800 IU vitamin D supplementation daily. There is a 
concern that excessive intake of calcium and/or vitamin D supplementation may 
encourage the formation of renal stone disease. All those who are on such 
supplementation should consume adequate fluids. Body weight low and excessive 
dieting is associated with low bone mineral status and increased fracture risk. 
Maintenance of a body mass index of not less than 19 kg/m2 is recommended for 
prevention of osteoporosis. Nutritional status maintenance of an adequate protein and 
energy intake is important especially in children and the elderly. Regular physical 
activities, in particular weight-bearing exercise is encouraged in all age groups in 
order to maximize peak bone mass, decrease age-related bone loss, and maintain 
muscle strength and balance. The individual’s health status should be taken into 
consideration when recommending an exercise programmed. 
 Pharmacological agents HRT, Selective Estrogen Receptor Modulators 
(SERMs) and bisphosphonates have shown to be effective in the prevention of 
osteoporosis. Prevention of the most osteoporosis-related fractures especially in the 
elderly are a consequence of decreased BMD and falls. Variety of factors may lead to 
a fall such as poor balance, reduced muscle strength, poor vision, disease of nervous 
and musculoskeletal systems, excessive alcohol consumption, certain medications 
(e.g. sedatives, anti-hypertensives) and hazards at  home (e.g. steps, inadequate 
lighting, slippery floors). Appropriate assessment and correction of risk factors for 
falls should be undertaken as well as protection of the hip by wearing hip protectors 
(Clinical Practice Guidelines on Management of Osteoporosis in Canada in2010). 
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1.4 Knowledge of Osteoporosis 
The way people manage their health care is influenced their knowledge of 
and attitude towards certain diseases (Andersen, 1995). Knowledge is the basics of 
understanding and reacting towards health issues. In terms of disease prevention – in 
this case, osteoporosis – knowledge of patients is integral in the preventing and 
reducing risk of fractures. The knowledge involved those on suitable physical 
activities, sufficient dietary requirement of calcium and vitamin D, fall prevention 
and osteoporosis test (Yeap et al., 2013). 
 The main focus of osteoporosis prevention is the identification of non-
osteoporotoc individuals who have high risk of developing osteoporosis. The second 
focus is early detection and prevention of future fractures. Generally, both involve 
osteoporosis-preventing behaviours (Lundy & Janes, 2009). Davis (2007) found that 
the sooner osteoporosis is detected, the lower chances of hospital admission due to 
osteoporotic fractures. Hence, this also stressed the importance of educating patients 
on the benefits of early screening and prevention.(Davis et al., 2007). 
While patient’s knowledge and osteoporosis preventive behaviour may be 
increased with the help of physicians (Cranney A. et al., 2008), and screening 
programs (Jensen et al., 2013; Yuksel et al., 2010), have found that patient’s 
education is the most effective way. However, this finding is contradicted by 
findings of other scholars such as study by Etemadifar in 2013,  who used different 
methodologies in their studies. The varying methods involving both qualitative and 
quantitative methods further add to the difficulty of reaching a consensus (Burke-
Doe et al., 2008; Etemadifar et al., 2013) The difference in the results also suggest 
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that knowledge is not the only component that affects behavioral changes. Beliefs, 
attitudes and values may also be a barrier to implement osteoporosis preventive 
efforts (Andersen, 1995). The Development and Validation of the Osteoporosis 
Prevention and Awareness Tool (OPAAT) in Malaysia can be used to identify 
individuals in need of osteoporosis educational intervention (Toh et al., 2015). 
1.5 Treatment of Osteoporosis                                                                              
The prevention of osteoporosis consists of three types: primary, secondary 
and tertiary prevention. Primary prevention involves general management that 
includes the assessment of the risk of falls and their prevention to avert the onset of 
disease (Chang J.T. et al., 2004). It includes encouraging adequate calcium and 
vitamin D intake and exercise (Body et al., 2011; Yeap et al., 2013). Secondary 
prevention includes early detection and treatment, fall prevention and use of anabolic 
agents while tertiary prevention focuses on treatment. At the stage of tertiary 
prevention, healthcare professionals are involved in the retraining and rehabilitation 
of the patients (National Institutes of Health  (NIH), 2001; Yeap et al., 2013).  
 
1.5.1 Pharmacological treatment of osteoporosis                                 
Every effort to increase BMD is important to delay the onset or slow the 
progression of osteoporosis complications (Maclean et al., 2008; National 
Osteoporosis Foundation, 2013). Many types of medications are used for the 
treatment of osteoporosis, based on an individualised assessment of the patient's risk 
factors and preferences. The goal of osteoporosis treatment is to improve BMD and 
reduce future fractures (Braddon & Phillips, 2004; Yeap et al., 2013). There are two 
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categories of osteoporosis medications: antiresorptive (anticatabolic) medications 
which either reduce bone resorption or inhibit bone turnover (by acting on 
osteoclasts); and anabolic medications which stimulate and increase the rate of new 
bone formation (by targeting osteoblasts) (National Osteoporosis Foundation, 2013; 
Rahmani & Morin, 2009; Yeap et al., 2013). Table 1.3 lists the commonly used 
medication in the treatment of osteoporosis. 
        Although these medications improve bone mass, the level of compliance and 
adherence is still poor. This, in turn, affects the effectiveness of the treatments (Gass 
& Dawson-Hughes, 2006; Kanis et al., 2008 b), and increases  mortality and 
morbidity (Bolland et al., 2010). The major pharmacological Interventions available 
in Malaysia are the bisphosphonates, strontium ranelate, denosumab, teriparatide, 
raloxifene, and hormone therapy. All of them increase BMD and reduce fractures  
when given with calcium and vitamin (Yeap et al., 2013).
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Table1.3: Medications used for the treatment of osteoporosis (Koda-Kimble et al., 2013; National Osteoporosis Foundation, 2013; Yeap 
et al., 2013). 
Classification/ Medication Mechanism Therapeutic note 
1-Antiresorptive medications                                                                                                      
Bisphosphonates 
Alendronate 
Etidronate 
Ibandronate 
pamidronate 
Riscdronate 
Zoiedronic acid 
Inhibit osteoclast activity, reduce bone 
turnover, reduces bone loss, increases 
bone density and reduces the risk of 
spine, hip and other broken bones. 
 Taken in the morning on an empty stomach with 6 to 8 
ounces of plain water, at least 30 minutes before having 
anything to eat or drink. 
  Patients must remain upright (sitting, standing or walking) 
during this 30-minute period. Should be used in patients 
taking corticosteroids to protect from developing OP. 
 
Estrogen therapy 
Reduce bone turnover, increase bone 
density in both the spine and hip, and 
reduce the risk of hip, spine and other 
fractures. 
 Can increase women risk of developing endometrial 
cancer, breast cancer, vascular thrombosis, cardiovascular 
risks, and heart disease.  
 Physicians usually prescribe hormone progesterone in 
combination with estrogen. It can cause vaginal bleeding, 
blood clots, breast tenderness and gallbladder disease. 
Selective estrogen 
Receptor modulators 
Raloxifene ,Tamoxifen, 
Testosterone 
Increases bone density and reduce the 
risk of spine and hip fractures. 
Side effects are not common; but it can cause hot flashes, leg 
cramps and deep vein thrombosis (blood clots). Raloxifene is 
not used in patients at increased risk for stroke, atrial fibrillation 
or uncontrolled hypertension (high blood pressure). It can 
reduce the risk of some types of breast cancer and endometrial 
cancer, as well as, reduce lipid profile. 
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Continued..                                                                 2-Anabolic medications 
Synthetic Parathyroid 
hormone (PTH) 
Teriparatide 
Increases the rate of bone formation, 
improve skeletal architecture and lower 
the risk of breaking bones and fracture 
in spine and throughout the skeleton. 
Can cause, leg cramps and dizziness, modest elevations in serum 
and urine calcium.  It is not to be given to people with metabolic 
bone diseases such as hyperparathyroidism and those with 
cancer that has spread to the bone. Bisphosphonates must be 
discontinued prior to treatment with Teriparatide. 
3-Vitamins and minerals 
Calcium 
Vitamin D 
Regulation of calcium 
absorption, muscle 
performance, balance, fall 
prevention, and bone health. 
Should be given in combination for optimal results. Vitamin D is available from 
sunlight, some foods and supplements. 
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1.6 Statement of the Problem 
Osteoporosis management is a lifelong process that requires effort from 
healthcare providers and patients. Patients are the key to a successful management. 
However, many complications can occur from a poor management. Patients must be 
proficient to successfully manage, maintain lifestyle changes, and make daily 
decisions for better healthcare. In addition, healthcare professionals must help 
patients to make a right decision and cope with the difficulties and barriers through 
education, support and advice (Funnell & Anderson, 2004; Levine, 2011).  
Osteoporosis is a growing health problem in Malaysia with a high cost in 
terms of economics and disability. It is estimated that 27000 people have a broken 
hip every year because of osteoporosis in Malaysia. It is worthwhile to note that hip 
fractures in females is double compared to males (Lau et al., 2001). Compared to 
other Asian countries, Malaysia showed high prevalence of osteoporosis (24.1%) in 
2005 (Loh & Shong, 2007). This may be due to rapid socio-economic growth, 
enormous urbanization and changes in dietary habits. 
Although numerous measures have been taken to improve bone health and 
osteoporosis management through published Malaysian guideline (Yeap et al., 2013), 
there is a lack of good bone health management. It is important to explore patients’ 
knowledge and awareness toward osteoporosis by identifying the source of 
information. Lack of awareness is the main reason for high prevalence of low bone 
mass (Doheny et al., 2007). Therefore, education is necessary to increase the level of 
Knowledge of patients who are culturally sensitive. 
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1.7 Significance of the Study 
The proportion of low bone mineral density is high among the general population in 
Penang. The incidence of osteoporosis in postmenopausal women is high especially 
in Malaysia. In this regard, there has been a shortage of data on the topic of the 
prevalence of osteoporosis condition among warfarin users in Penang. There are few 
academic and empirical published papers regarding osteoporosis knowledge and 
most of reviews on this subject have been conducted in western countries. In Penang, 
there has been a lack of data on the topic of patients knowledge regarding 
osteoporosis among warfarin users. Rare results have been published for the 
association  of bone mineral density measurement and osteoporosis knowledge in 
patients taking  warfarin for more than one year. 
The clinical finding of this study will provide the fundamental basis for health 
care professionals to understand the logical and the appropriate utilization of health 
services in the management of osteoporosis among warfarin users and non-users in 
Malaysia. The outcomes of the present study will lead to better patient care. It will 
enhance patients’ quality of life, and avoid possible adverse effects. 
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1.8 Objectives of the Study 
1. To assess the incidence of osteoporotic conditions between warfarin users 
(patients) and non-warfarin users (control) using QUS. 
2. To assess the risk factor of OP using QUS parameters (like T-scores) this is 
related to BMD between warfarin users and the control group. 
3. To assess the potential factors that influence BMD values including warfarin 
use and the socio-demographic data.  
4. To assess the osteoporotic knowledge levels using OKT tool and its 
associated factors. 
1.9 Scope of the Study 
The present study was a case-control study, which aimed at an investigation 
incidence of osteoporosis between users and non- users warfarin groups and risk 
factors affecting on OP. Also to determine the knowledge levels between two groups 
and its associated factors. 
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2  CHAPTER 2   
3 LITERATURE  REVIEW    
2.1 Osteoporosis 
Many studies considerd the osteoporosis presents as a serious and growing 
public health problem, as its prevalence continues to increase worldwide (Cashman, 
2007; National Osteoporosis Foundation, 2013). Common sites of fracture include 
spine, hip, forearm and proximal hummers. Fractures of the hip incur the greatest 
morbidity and mortality and give rise to the highest direct costs for health services. 
Their incidence increases exponentially with age. Osteoporotic fractures, at other 
sites, are generally of less economic significance but they also give rise to significant 
morbidity and, in some instances, to increased mortality. They occur more 
commonly than hip fractures at younger ages  . 
A study by Johnell & Kanis (2006) showed the probability of osteoporotic 
fractures in women at the age of 50 years was exceeds 40% in developed countries. 
For hip fracture alone, the remaining lifetime probability at the age of 50 years 
exceeds 20% in women in these countries. In many regions of the world, the risks in 
men are about half of women. Over and above changes in population demography, 
the age- and sex-specific incidence of osteoporotic fractures appears to be increasing 
in developing countries. This is anticipated that the expected burden of osteoporotic 
fractures over the next 50 years will increase twice as much as the current situation 
(Johnell & Kanis, 2006). 
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The study by Wark (1999) illustrated the  number of osteoporotic fractures 
would increase in both men and women (by more than 3-fold over the next 50 years) 
due to the aging population. It increases mostly outside of Europe and the US, 
particularly in Asia and Latin America (Wark, 1999). 
A study by  Lee & Khir (2007) which showed The incidence of hip fracture in 
Malaysia among individuals above 50 years of age was 90 per 100,000. There was a 
marked increase in the incidence among the older age group. The incidence of hip 
fracture is consistently higher in women. 63% of patients presenting with hip 
fractures were Chinese. It was 20% among Malays and 13% among Indians. Race-
specific incidence data showed that the fracture rates are the highest among Chinese 
(160 per 100 000) followed by Indians (150 per 100 000) and Malays (30 per 100 
000). Females were twice as more affected than males. Race and sex-specific 
incidence data showed that the incidence was the highest among Chinese females 
(220 per 100 000), followed by Indian females (200 per 100 000). The age-specific 
incidence was 500 per 100 000 for patients above 75 years, compared to 10 per 100 
000 in those between 50 and 54 years (Lee J.K. & Khir, 2007). 
Another study by Delaney (2006) mentioned that, Bone mass reaches to the 
peak level in the third decade of life and the rate of decline in BMD accelerates with 
advancing age and postmenopausal status in women (Delaney, 2006; Ryan, 1997). 
A study which had been done in Malaysia in 2007 showed the prevalence of 
osteoporosis in Malaysia was reported as 24.1% in 2005, predominantly affecting the 
hip (Loh & Shong, 2007), while the rates of hip fracture are twofold higher in Hong 
Kong (Gullberg et al., 1997). In contrast, the prevalence of osteoporosis was found 
